Valuation : Gilead Sciences, Inc.

Market Cap 180B 154B 146B 133B 248B 17,167B 250B 1,735B 668B 8,707B 674B 660B 27,657B P/E 2026 *
-43.8x
P/E 2027 * 18x
Enterprise Value 196B 169B 159B 145B 271B 18,768B 274B 1,897B 730B 9,519B 737B 721B 30,237B EV / Sales 2026 *
6.4x
EV / Sales 2027 * 5.77x
Free-Float
99.88%
Yield 2026 *
2.27%
Yield 2027 * 2.31%
1 day-0.62%
1 week-4.78%
Current month-1.75%
1 month+5.90%
3 months+14.23%
6 months-1.52%
Current year+17.14%
1 week 143.5
Extreme 143.5
148.65
1 month 133.3
Extreme 133.295
152.55
Current year 116.88
Extreme 116.88
157.29
1 year 108.46
Extreme 108.4601
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 28/02/2019
Director of Finance/CFO 56 31/10/2019
Compliance Officer - 17/12/2025
Director TitleAgeSince
Director/Board Member 58 18/08/2016
Director/Board Member 73 31/12/2017
Director/Board Member 72 08/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Sell

Chief Executive Officer

-15,000 0.0012%
26/08/26 Exercice

Director

54,000 0.0043%
20/08/26 Exercice

Director

15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.63%-4.78%+21.99%+86.63% 180B
+0.01%-2.50%+48.17%+88.15% 1,001B
+0.07%-3.14%+49.36%+63.90% 642B
+0.86%+0.04%+16.50%+72.13% 451B
-0.38%-3.59%+28.24%+35.57% 340B
-0.09%-13.54%+10.08%+26.87% 263B
-0.43%-2.48%-2.07%+11.48% 247B
-0.74%-13.00%+34.53%+45.33% 207B
-3.44%-7.51%-20.08%-59.58% 197B
-0.45%-3.46%+10.49%-19.07% 158B
Average -0.49%-5.38%+19.72%+35.14% 368.39B
Weighted average by Cap. -0.19%-4.63%+29.28%+52.65%

Financials

2026 *2027 *
Net sales 30.69B 26.39B 24.9B 22.69B 42.41B 2,934B 42.79B 297B 114B 1,488B 115B 113B 4,727B 32.68B 28.11B 26.52B 24.16B 45.16B 3,125B 45.57B 316B 122B 1,585B 123B 120B 5,034B
Net income -4.27B -3.68B -3.47B -3.16B -5.91B -409B -5.96B -41.31B -15.9B -207B -16.05B -15.7B -658B 10.28B 8.84B 8.34B 7.6B 14.2B 982B 14.33B 99.3B 38.22B 498B 38.58B 37.74B 1,583B
Net Debt 16.75B 14.4B 13.59B 12.38B 23.14B 1,601B 23.35B 162B 62.28B 812B 62.88B 61.51B 2,579B 9.12B 7.85B 7.4B 6.74B 12.61B 872B 12.72B 88.18B 33.94B 442B 34.26B 33.52B 1,405B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
11/09/26 US$143.91 -0.62% 1,445,430
10/09/26 US$144.81 -0.58% 6,019,851
09/09/26 US$145.65 -0.68% 4,583,213
08/09/26 US$146.64 -2.88% 6,080,502
04/09/26 US$151.00 -0.15% 6,181,783
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
144.81USD
Average target price
158.15USD
Spread / Average Target
+9.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!